Carotid-Femoral Pulse Wave Velocity Is Associated With Cerebral White Matter Lesions in Type 2 Diabetes

ESBEN LAUGESSEN, MD
PERNILLE HOYEM, MD
BRIAN STAUSSBOE-GRØN, MD, PHD
ANDERS MIKKELSEN, MSC, BME
SAMUEL THRYSOE, MSC, BME, PHD
MOGENS ERLANDSEN, MSC
JENS S. CHRISTIANSEN, MD, DMSCI
SOREN T. KNUDSEN, MD, PHD, DMSCI
KLAVS W. HANSEN, MD, DMSCI
WON Y. KIM, MD, PHD, DMSCI
TROELS K. HANSEN, MD, PHD, DMSCI
PERNILLE HØYEM, MD
ESBEN LAUGESEN, MD

OBJECTIVE—Patients with type 2 diabetes have a high incidence of cardiovascular events including stroke. Increased arterial stiffness (AS) predicts cardiovascular events in the general population. Cerebral white matter lesions (WMLs) are associated with an increased risk of stroke. It is unknown whether AS in patients with type 2 diabetes is associated with WMLs.

RESEARCH DESIGN AND METHODS—We examined 89 patients recently diagnosed with type 2 diabetes (<5 years) and 89 sex- and age-matched controls. AS was assessed with carotid-femoral pulse wave velocity (PWV). WMLs were identified using magnetic resonance imaging and graded qualitatively with the Breiteler scale (no slight changes = 0, moderate changes = 1, severe changes = 2) and semiquantitatively.

RESULTS—The diabetic population had excellent glycemic control (HbA1c, 6.5% [6.2–6.8]; median [interquartile range (IQR)] and had, compared to the controls, lower office blood pressure (BP) (127 ± 12/79 ± 8 vs. 132 ± 14/84 ± 10 mmHg) and total cholesterol (4.3 [3.9–4.7] vs. 5.6 [5.1–6.4]; mmol/L; median [IQR], P < 0.01 for all). Despite this, PWV was higher in the patients with diabetes compared with controls (9.3 ± 2.0 vs. 8.0 ± 1.6 m/s; P < 0.001). PWV was associated with Breiteler score (OR 1.36 [95% CI 1.17–1.58]; P < 0.001) and WML volume (OR 1.32 [95% CI 1.16–1.51]; P < 0.001) per 1 m/s increase in PWV. These associations remained significant when adjusted for age, sex, diabetes, 24-h mean arterial BP, BMI, heart rate, and use of antihypertensives and statins (Breiteler score: OR 1.28 [95% CI 1.03–1.56]; P < 0.05 and WML volume: OR 1.30 [95% CI 1.06–1.58]; P < 0.05).

CONCLUSIONS—PWV was higher among patients with well-controlled type 2 diabetes compared with controls and was independently associated with WMLs. PWV may represent a clinically relevant parameter in the evaluation of cerebrovascular disease risk in type 2 diabetes.

Diabetes Care 36:722–728, 2013

Despite intensified treatment, patients with type 2 diabetes have a significantly higher incidence of cardiovascular events, including stroke, compared with patients without diabetes (1–3). Identifying new risk factors for incident cardiovascular disease, which add prognostic information to established risk factors, is important to improve risk stratification and enable timely initiation of individually tailored preventive measures in this high-risk population (4). Increased arterial stiffness, as indicated by increased pulse wave velocity (PWV), is an independent predictor of cardiovascular morbidity and mortality and total mortality in various non-diabetic populations (5–11). In patients with diabetes, PWV independently predicts cardiovascular and total mortality (12). Several studies have found cerebral white matter lesions (WMLs) to be associated with the risk of stroke (13). Nevertheless, it remains unknown whether PWV in patients with type 2 diabetes is associated with the severity of WMLs. In this study of a sample of patients with recently diagnosed type 2 diabetes and a sex- and age-matched control group, our aims were to (1) compare PWV and established cardiovascular risk factors and (2) study the association between PWV and WMLs.

RESEARCH DESIGN AND METHODS

Subjects
One hundred patients with type 2 diabetes and 100 controls matched individually for sex and age were included in this study. The patients were recruited consecutively from the outpatient clinics at Aarhus University Hospital, Aarhus, Denmark. Inclusion criteria were age >18 years, diagnosis of type 2 diabetes according to World Health Organization criteria (14), and known duration of diabetes <5 years. The control subjects were recruited by advertising in the local press, and undiagnosed diabetes was excluded by fasting glucose and oral glucose tolerance tests. Subjects with impaired fasting glucose (nine participants), impaired glucose tolerance (three participants), or both (two participants) were accepted as control subjects. Exclusion criteria for both patients with diabetes and controls were acute or chronic infectious disease, end-stage renal failure, pregnancy or lactation, prior or current cancer, and contraindications to magnetic resonance imaging (MRI) (claustrophobia, magnetic material in the body, and body weight >120 kg). PWV data were not recordable in four participants because of atrial fibrillation and in three participants because of obesity. MRI data were not available for four participants because of previously unrecognized claustrophobia (in two of these participants PWV was not recordable because of technical problems). Accordingly,
Examinations were conducted from 9 A.M. until 1 P.M. after a minimum of 5 min rest in a quiet room. The study subjects had abstained from smoking and intake of tea, coffee, or other caffeinated beverages for at least 3 h before the examinations. At least 2 h elapsed between breakfast and the examinations.

Measurements of PWV were performed using an applanon tonometer (SPT-301B; Millar, Houston, TX) and SphygmoCor equipment and software, version 8.0 (AtCor Medical, Sydney, Australia). After a minimum of 5 min of rest in the supine position, the carotid-femoral PWV was determined by sequential electrocardiogram-referenced recordings of the pulse wave at the carotid and the femoral artery by the tonometer. The transit time was determined by the intersecting tangent algorithm method (15), and the path length was calculated by subtracting the distance between the site of the carotid artery pulse measurement and the sternal notch from the distance between the site of the femoral artery pulse measurement and the sternal notch, all measured directly using a tape measure. The mean of two PWV measurements was calculated. Within-subject coefficient of variation for PWV was 5.1%.

Office blood pressure (BP) was measured on the right arm, and mean systolic and diastolic BPs were calculated as the average of three measurements obtained after a minimum of 5 min of rest in the seated position. Arm circumference was assessed using a tape measure and an appropriately sized cuff. BP was measured by a Rieter Champion N automatic blood pressure monitor (Rieter GmbH, Jungingen, Germany) or a Speidel & Keller mercury sphygmomanometer (Speidel & Keller, Welch Allyn, Jungingen, Germany). Pulse pressure was calculated as systolic BP minus diastolic BP, and mean arterial pressure as diastolic BP + (systolic − diastolic)/3.

Ambulatory BP was monitored for 24 h using Spacelabs 90217 (Spacelabs HealthCare, Issaquah, WA). BP was measured at 20-min intervals during the day and night.

The calculation of day and night BP was based on patients’ individual diary recordings of awake and sleeping hours. Recordings with more than three missing hours (maximum of 1 h during the night) were excluded from the analysis. Visit-to-visit BP coefficients of variation are 2–5% (16,17).

Brain MRI. Brain MRI was performed with an eight-channel SENSE head coil on a 1.5-T MRI scanner (Achieva, Philips, Best, Netherlands) to obtain axial T2-flair-weighted scans with a slice thickness of 5 mm (T2 flair echo time, 130 ms; repetition time, 6,000 ms; inversion time, 2,200 ms; echo train length [number per repetition time], 19; flip angle, 90 degrees; number of averages, 2). The magnetic resonance images were evaluated by an experienced radiologist who was blinded to the subjects’ diabetic/control status. WMLs were defined as areas of brain parenchyma with an increased signal on the T2-weighted scans but without significant volume loss. The WMLs were assessed both qualitatively and semiquantitatively. Qualitatively, the patients were graded 0–2 according to the scale introduced by Breteler et al. (18) (0–4 punctate WMLs = 0, >4 punctate WMLs but no confluent lesions = 1, presence of confluent WMLs regardless of number of punctate lesions = 2). This scale is simple and robust, with a high interrater reliability (19). In addition, the volume of the WMLs was assessed semiquantitatively as area of WMLs multiplied by the slice thickness. Measurements were performed using the Osirix 4.0 Dicom viewer (20). The radiologist and a biomedical engineer, both blinded to the diabetic/control status of the patients, in cooperation recorded the areas of the WMLs. The areas of all individual confluent lesions were measured. The size of a typical punctate WML was estimated by using the mean area of a representative sample (36 lesions). The areas of measured punctate WMLs from five randomly selected patients with diabetes and five controls were randomly distributed around the estimated mean area, with no obvious indication of difference in size of WMLs between the two groups. Hence, the total estimated WML volume in the individual patient was calculated as follows:

\[
\text{WML volume} = \text{(total number of punctate lesions in the patient \times average area of punctate lesion)} + \text{(total areas of confluent lesions in the individual patient \times slice thickness)}.
\]

Cerebral infarctions were defined as areas with volume loss surrounded by signals consistent with glosis and were classified as lacunar when the size was less than 15 mm. Urinary albumin excretion. Urinary albumin excretion was evaluated by albumin-to-creatinine ratios in three morning urine samples. Patients were classified as microalbuminuric when at least two of three samples had urinary albumin-to-creatinine ratios of 2.5–25 mg/mmol (men) and 3.5–35 mg/mmol (women).

**Statistics**

Differences in means were assessed by paired t tests. Assumption of normal distributions was tested by histograms and Q–Q plots. Skewed data (HbA1c, total cholesterol, triglycerides, and urine albumin-to-creatinine ratio) were log-transformed before t tests were performed. The estimated volumes of WMLs were not normally distributed even if log-transformed. Thus WML volumes were categorized as low, medium, or high (operationalized as 1st to 50th percentile, 51st to 75th percentile, and 76th to 100th percentile, respectively, because of the skewed distribution of WMLs, with a substantial part of the sample having no or few WMLs) to enable ordinal regression analysis with adjustment for matching and confounders. Test for trend was calculated by the nptrend-test in Stata software. Difference in Breteler score between the two groups was tested with a signed rank test. Baseline data are presented as means ± SD or median (25th percentile; 75th percentile) for skewed data. A two-tailed P value of less than 0.05 was considered statistically significant. Data were analyzed with software from Stata (version 11; StataCorp LP, College Station, TX).

**RESULTS**—Patient characteristics are presented in Table 1. The patients with diabetes were recently diagnosed and were overweight but had good glycemic control. There was no difference between the two groups regarding smoking habits, but a significantly higher proportion of the diabetic population was taking antihypertensive and cholesterol-lowering treatment (Table 1). Accordingly, the diabetic group had significantly lower office BP and cholesterol levels.

Twenty-four hour ambulatory (ABPM) systolic and diastolic BP were comparable between the two groups, whereas 24-h ABPM of pulse pressure was significantly higher in the diabetic group, primarily because of a higher pulse pressure at night in the diabetic group (Table 1). The diabetic group also was characterized by a
PWV and WMLs in type 2 diabetes

Table 1—Patient characteristics

|                                | Patients with diabetes | Controls | P value |
|--------------------------------|------------------------|----------|---------|
| **Sex, n**                     |                        |          |         |
| Men                            | 46                     | 46       |         |
| Women                          | 43                     | 43       |         |
| **Age (years)**                | 59 ± 10                | 59 ± 10  |         |
| **Diabetes duration (years)**  |                        |          |         |
| Median                         | 1.8                    | —        |         |
| 25th percentile                | 0.8                    | —        |         |
| 75th percentile                | 3.1                    | —        |         |
| **HbA1c, %**                   |                        | <0.0001  |         |
| Median                         | 6.5                    | 5.7      |         |
| 25th percentile                | 6.2                    | 5.5      |         |
| 75th percentile                | 6.8                    | 5.8      |         |
| **BMI (kg/m²)**                | 30 ± 5                 | 26 ± 4   | <0.0001 |
| **Smoking, n**                 |                        | 0.95     |         |
| Current                        | 18                     | 18       |         |
| Previous                       | 32                     | 30       |         |
| Never                          | 39                     | 41       |         |
| **Statin use, n**              |                        | <0.001   |         |
| Yes                            | 68                     | 16       |         |
| No                             | 21                     | 73       |         |
| **Antihypertensive treatment, n** |                      | <0.001   |         |
| Yes                            | 56                     | 25       |         |
| No                             | 33                     | 64       |         |
| **Total cholesterol (mmol/L)** |                        | <0.0001  |         |
| Median                         | 4.3                    | 5.6      |         |
| 25th percentile                | 3.9                    | 5.1      |         |
| 75th percentile                | 4.7                    | 6.4      |         |
| **LDL-cholesterol (mmol/L)**   | 2.2 ± 0.7              | 3.4 ± 1.0| <0.0001 |
| **HDL-cholesterol (mmol/L)**   | 1.4 ± 0.3              | 1.7 ± 0.6| 0.0001  |
| **Triglycerides (mmol/L)**     |                        | 0.03     |         |
| Median                         | 1.4                    | 1.2      |         |
| 25th percentile                | 1.1                    | 1.0      |         |
| 75th percentile                | 1.6                    | 1.6      |         |
| **Urine albumin/creatinine ratio (mg/mmol)** |          | 0.0001   |         |
| Median                         | 0.40                   | 0.25     |         |
| 25th percentile                | 0.28                   | 0.17     |         |
| 75th percentile                | 0.98                   | 0.40     |         |
| **Office measurement (mmHg)**  |                        |          |         |
| Systolic BP                    | 127 ± 12               | 132 ± 14 | <0.01   |
| Diastolic BP                   | 79 ± 8                 | 84 ± 10  | <0.001  |
| Pulse pressure                 | 47 ± 10                | 48 ± 10  | 0.72    |
| **24-h ABPM (mmHg)**           |                        |          |         |
| Systolic BP                    | 126 ± 11               | 125 ± 12 | 0.46    |
| Diastolic BP                   | 76 ± 7                 | 76 ± 7   | 0.17    |
| Pulse pressure                 | 52 ± 8                 | 49 ± 9   | 0.03    |
| Mean arterial pressure         | 92 ± 8                 | 93 ± 8   | 0.72    |
| **Daytime ABPM (mmHg)**        |                        |          |         |
| Systolic BP                    | 131 ± 11               | 130 ± 12 | 0.78    |
| Diastolic BP                   | 78 ± 8                 | 80 ± 8   | 0.11    |
| Pulse pressure                 | 53 ± 9                 | 50 ± 9   | 0.08    |
| **Nighttime ABPM (mmHg)**      |                        |          |         |
| Systolic BP                    | 116 ± 11               | 112 ± 11 | 0.02    |
| Diastolic BP                   | 66 ± 7                 | 66 ± 7   | 0.97    |
| Pulse pressure                 | 49 ± 9                 | 46 ± 8   | 0.003   |
| Heart rate (bpm)               |                        |          |         |
| Office                         | 67 ± 10                | 62 ± 11  | 0.001   |
| 24 h                           | 73 ± 10                | 68 ± 9   | 0.002   |

Values provided as mean ± SD unless otherwise indicated. higher urinary albumin-to-creatinine ratio than the control group. The patients with diabetes had significantly higher resting heart rate and 24-h ABPM heart rate than the controls (Table 1). Three patients in the diabetic group and two patients in the control group were classified as microalbuminuric. PWV in the diabetic group was significantly higher than in the control group (9.3 ± 2.0 vs. 8.0 ± 1.6 m/s; P < 0.0001), as shown in Fig. 1, which also depicts office and 24-h ABPM of systolic BP and night pulse pressure. PWV increased with Breteler score (P < 0.001 for trend; Fig. 2). In unadjusted ordinal regression analysis, PWV predicted Breteler score, both overall and in the diabetic and control groups (Table 2). The association remained significant after adjustment for age, sex, diabetes, 24-h mean arterial BP, BMI, 24-h heart rate, and use of antihypertensives and statins (Table 2). Adjustment for mean office BP, systolic BP (24-h ABPM or office measurement), or pulse pressure (office measurement, 24-h ABPM, day or night values) instead of 24-h mean BP did not alter this association. Similarly, adjustment for resting heart rate instead of 24-h heart rate or additional inclusion of smoking status or urinary albumin-to-creatinine ratio did not alter the associations significantly. In stratified analysis, PWV independently predicted Breteler score in the diabetic group but not in the control group (Table 2). In the diabetic group, the association remained significant even after inclusion of HbA1c, duration of diabetes, or treatment modality in the model (P < 0.05 for all). Testing for interaction between PWV and diabetic/control group, however, was not significant (P = 0.67).

PWV independently predicted increasing WML volume in unadjusted ordinal logistic regression analysis, both overall and in the diabetic and control groups (Table 2). The association remained statistically significant after adjustment for age, sex, diabetes, 24-h mean arterial BP, BMI, 24-h heart rate, and use of antihypertensive treatment and statins (Table 2). Adjustment for mean office BP, systolic BP (24-h ABPM or office measurement), or pulse pressure (office measurement, 24-h ABPM, day or night values) instead of 24-h mean BP did not alter this association. Similarly, inclusion of smoking or urinary albumin-to-creatinine ratio did not alter the associations significantly. In stratified analysis, PWV was independently associated with WML volume in the diabetic group but
not in the control group (Table 2). However, test for interaction between PWV and diabetic/control group was nonsignificant ($P = 0.85$).

There was no significant difference between the diabetic group and the control group with regard to Breteler score (48/31/10 vs. 50/26/13; $P = 0.64$). Similarly, the volume of WMLs was not significantly different between the diabetic and the control groups (mean difference $0.3 \text{ cm}^3$ [95% CI $-1.2$ to $0.7 \text{ cm}^3$]; $P = 0.55$). In the control group, when comparing participants with impaired fasting glucose or impaired glucose tolerance with participants with normoglycemia, there was neither a significant difference in Breteler score or WML volume ($P = 0.86$ and $P = 0.80$, respectively).

Nineteen participants (11 patients with diabetes and 8 controls) had evidence of cerebral infarctions on the MRI scans. In the diabetic group, 6 of the 11 infarctions had been symptomatic; 5 were silent and only identified on the MRI scans. In the control group, three of the eight infarctions had been symptomatic, and five were silent and only identified on the MRI scans. Subjects with cerebral infarctions had significantly higher PWV than subjects without ($9.9 \pm 1.7$ vs. $8.5 \pm 1.9 \text{ m/s}; P = 0.002$). The prevalence of infarctions was significantly higher in patients with PWV above versus below the median value of $8.4 \text{ m/s} (P = 0.001)$. Infarctions were present in 16 of 88 participants with a PWV above versus 3 of 90 participants with a PWV below the median value. Hence, the prevalence of infarctions was 5.5 times higher in patients with PWV above the median value compared with patients with PWV below the median value.

**Figure 1**—PWV and BP in 89 patients with type 2 diabetes and 89 sex- and age-matched controls. A: PWV. B: Office systolic BP. C: 24-h ABPM. D: Night pulse pressure.
and cholesterol levels are modified markers. Because glycemic control, BP, what is revealed by conventional risk vascular risk profile patients with diabetes (25). It is interesting that there was no significant difference in Breteler score or estimated WML volume between the two groups. We have no obvious explanation for this finding. It might reflect the multifactorial pathophysiology underlying the development of WMLs. A higher prevalence of some unidentified risk factors for WMLs in the control group could have influenced the WML burden in this group, yet the exact nature of these remain elusive given the well-matched groups (Table 1). The third finding was an increased prevalence of cerebral infarctions in patients with PWV above the median value (8.4 m/s). The relatively low number of cerebral infarctions (19 subjects), however, precluded adjustment for confounders; hence these findings should be interpreted cautiously and the results should be confirmed in a larger sample before conclusions regarding the predictive ability of PWV for nonfatal stroke in patients with diabetes can be made.

Several studies have shown that WMLs, especially confluent WMLs, are associated with an increased risk of cerebral infarctions (13,26,27). The pathogenesis of cerebral WMLs and the chain of events causing clinical infarctions are multifactorial and remain incompletely elucidated (26,28). However, ischemic

Table 2—Association of carotid-femoral PWV with qualitative (Breteler) and semiquantitative (WML volume) grading of cerebral WMLs in ordinal logistic regression analysis

| Breteler score | Unadjusted odds ratio (95% CI) per 1 m/s increase in PWV | Adjusted odds ratio (95% CI) per 1 m/s increase in PWV | P value |
|----------------|----------------------------------------------------------|----------------------------------------------------------|---------|
| All             | 1.36 (1.17–1.58)                                          | 1.28 (1.03–1.60)                                          | <0.05   |
| Patients with diabetes | 1.42 (1.13–1.79)                                      | 1.39 (1.02–1.88)                                      | <0.05   |
| Controls        | 1.37 (1.10–1.71)                                          | 1.1 (0.78–1.59)                                          | 0.56    |
| WML volume      |                                                          |                                                          |         |
| All             | 1.32 (1.16–1.51)                                          | 1.30 (1.06–1.58)                                          | <0.05   |
| Patients with diabetes | 1.37 (1.13–1.67)                                      | 1.43 (1.08–1.91)                                      | <0.05   |
| Controls        | 1.38 (1.11–1.73)                                          | 1.10 (0.76–1.61)                                          | 0.60    |

*Adjusted for age, sex, diabetes, 24-h mean arterial BP, BMI, 24-h heart rate, and use of antihypertensives and statins.
injury to the white matter presumably plays an important role in the development of WMLs. Cross-talk between the macro- and microcirculation seems to be central to this process. When the pulse wave travels along the arterial tree, reflected waves are generated at sites of impedance mismatch. This occurs at bifurcations and at the interface between arteries with low and high impedance, such as between the elastic aorta and the stiffer carotid arteries. This mechanism protects the microcirculation from excessive transmission of pulsatile energy. Nevertheless, with increasing aortic stiffness, the central pulse pressure increases and the impedance mismatch decreases, resulting in a higher transmission of pulsations into the low-impedance microvasculature of the brain (29,30). This may promote arterial wall remodeling (arteriosclerosis) with resulting smaller lumen and reduced vasodilatory reserve. Increased vascular resistance in response to increased pulse pressure with unchanged mean arterial pressure will reduce mean blood flow, potentially causing chronic hypoperfusion in the supplied areas of the brain. Furthermore, the concurrence of reduced vasodilatory reserve and the labile BP, often seen with increasing arterial stiffness, increases the risk of episodes of transient reductions of mean arterial pressure below the autoregulatory range, with ensuing episodes of microvascular ischemia (26,29). The potential combined effect of chronic and acute episodes of hypoperfusion and ischemia can induce damage to the white matter and disrupt the blood brain barrier, with leakage of plasma into the white matter. These alterations may manifest as diffuse areas of myelin rarefaction (i.e., WMLs) and localized areas of necrosis and cavitation (i.e., lacunes) (13,26,29).

A recent meta-analysis of population studies found high levels of WMLs to be associated with a significantly increased risk of stroke (OR 3.1 [95% CI 2.3–4.1]; P < 0.001), which is even higher in high-risk populations with established atherosclerotic disease (7.4 [2.4–22.9]; P = 0.001) (13). Specific data for diabetic patients have not been published.

The association between PWV and WMLs has, to the best of our knowledge, not previously been studied in a well-defined sample of patients with type 2 diabetes and compared with nondiabetic controls. Previous studies have investigated the association between PWV and WMLs in other patient groups and have not found a uniform tendency. In some studies, PWV was reported to be independently associated with WMLs (31–35), whereas in others it was not (36–40). These results probably reflect both the multifactorial pathophysiology underlying the development of WMLs and the methodological differences regarding assessment of PWV and WML. Overall, it seems that the association between PWV and WMLs is most pronounced in high-risk populations (elderly people, patients with cerebral infarctions, and patients with type 1 diabetes). We extend this association to patients with newly diagnosed type 2 diabetes. In stratified analysis, the association between PWV and WMLs was statistically significant only in the diabetic population but, it should be stressed that testing for interaction between diabetes and PWV was not significant. The implication of the nonsignificant interaction term is that no firm conclusions regarding differences in the strength of the association between PWV and WMLs in the diabetic group versus the control group can be made based on this study. However, the data do suggest that the underlying pathophysiology associating PWV and WMLs might be different in patients with diabetes compared with those without diabetes, potentially with a closer association in patients with diabetes than in controls. Further clarification of the differences in this association must await future studies.

In conclusion, we found increased PWV in a well-regulated sample of patients with type 2 diabetes compared with a sex- and age-matched control group. Moreover, increased PWV was independently associated with severity of WMLs even after adjustment for established cardiovascular risk markers. Thus, our findings support the potential added predictive value of PWV in risk stratification above conventional risk factors.

Acknowledgments—This work was supported by research grants from The Novo Nordisk Foundation, the A.P. Moller Foundation for the Advancement of Medical Science, the Beckett Foundation, and the Aase and Einar Danielsen Foundation.

No potential conflicts of interest relevant to this article were reported.

E.L. generated the study hypothesis; developed the study design; acquired, analyzed, and interpreted data; and drafted and revised the manuscript. P.H. developed the study design, acquired data, critically revised the manuscript, and obtained funding. B.S.-G. analyzed and interpreted data, provided technical support, and critically revised the manuscript. A.M. analyzed data, provided technical support, and critically revised the manuscript. S.T. developed the study design, provided technical support, and critically revised the manuscript. M.E. provided statistical support, interpreted data, and critically revised the manuscript. J.S.C. developed the study design, provided administrative support, obtained funding, and critically revised the manuscript. S.T.K and K.W.H interpreted data and critically edited and revised the manuscript. W.Y.K. developed the study design, interpreted data, provided technical support, and critically revised the manuscript. P.L.P. developed the study hypothesis, analyzed and interpreted data, handled supervision, provided administrative support, and critically revised the manuscript. E.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank laboratory technicians Merete Møller and Lisa Buus, from the Medical Research Laboratory at the Department for Endocrinology and Internal Medicine, Aarhus University Hospital, for excellent technical assistance.

References

1. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117: 1945–1954
2. Seshasai SR, Kapote S, Thompson A, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–841
3. Bejot Y, Giroud M. Stroke in diabetic patients. Diabetes Metab 2010;36(Suppl 3): S84–S87
4. Cruden NL. Premature coronary artery disease and arterial stiffness: too soon to speculate? Heart 2012;98:431–432
5. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236–1241
6. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al.; Health ABC Study. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;111:3384–3390
7. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434–2439
PWV and WMLs in type 2 diabetes

8. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664–670
9. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010;121:505–511
10. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006;113:657–663
11. Maldonado J, Pereira T, Polónia J, Silva JA, Morais J, Marques M; Participants in the EDIVA Project. Arterial stiffness predicts cardiovascular outcome in a low-to-moderate cardiovascular risk population: the EDIVA (Estudo de Distensibilidade Vascular) project. J Hypertens 2011;29:669–675
12. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002;106:2085–2090
13. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666
14. World Health Organization Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus [Internet]. 1999. Geneva: WHO. Available from http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf. Accessed 18 October 2012
15. Hermeling E, Reesink KD, Reneman RS, Hoeks AP. Measurement of local pulse wave velocity: effects of signal processing on precision. Ultrasound Med Biol 2007;33:774–781
16. Hansen KW, Poulsen PL, Mogensen CE. 24-h blood pressure recordings in type 1 diabetic patients. J Diabetes Complications 1995;9:237–240
17. Felício JS, Pacheco JT, Ferreira SR, et al. Reproducibility of ambulatory blood pressure monitoring in hypertensive patients with type 2 diabetes mellitus. Arq Bras Cardiol 2007;88:206–211
18. Breteler MM, van Amerongen NM, van Swieten JC, et al. Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study. Stroke 1994;25:1109–1115
19. Scheltens P, Erkinjunti T, Leys D, et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol 1998;39:80–89
20. Rosset A, Spadola L, Raith O. OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging 2004;17:205–216
21. Vlachopoulos C, Aznáurídez K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318–1327
22. Ait-Oufella H, Collin C, Bozec E, et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. J Hypertens 2010;28:2336–2341
23. Lautem P, Mestre C, Lievre M, Gressard A, Milon H. Heart rate: an important confounder of pulse wave velocity assessment. Hypertension 2002;39:1083–1087
24. Peterson CM, Jones RL, Esterly JA, Wantz GE, Jackson RL. Changes in basement membrane thickening and pulse volume concomitant with improved glucose control and exercise in patients with insulin-dependent diabetes mellitus. Diabetes Care 1980;3:586–589
25. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008;51:527–539
26. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701
27. Schmidt R, Grazer A, Enzinger C, et al. MRI-detected white matter lesions: do they really matter? J Neural Transm 2011;118:673–681
28. Rajapakse A, Rajapakse S, Sharma JC. Is investigating for carotid artery disease warranted in non-cortical lacunar infarction? Stroke 2011;42:217–220
29. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 2008;105:1652–1660
30. Nichols WW, O’Rourke MF, Vlachopoulos C. McDonald’s Blood Flow in Arteries. Theoretical, experimental and clinical principles. 6th ed. London, Arnold, 2011, p. 397–411
31. Kuo HK, Chen CY, Liu HM, et al. Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults. Int J Cardiol 2010;143:184–191
32. van Elderen SG, Brandts A, Westenberg JJ, et al. Aortic stiffness is associated with cardiac function and cerebral small vessel disease in patients with type 1 diabetes mellitus: assessment by magnetic resonance imaging. Eur Radiol 2010;20:1132–1138
33. Hatanaka R, Ohara T, Watabe D, et al. Association of arterial stiffness with silent cerebrovascular lesions: the Ohasama study. Cerebrovasc Dis 2011;31:329–337
34. Henskens LH, Kroon AA, van Oostenbrugge RJ, et al. Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension 2008;52:1120–1126
35. Coutinho T, Turner ST, Kuloo IJ. Aortic pulse wave velocity is associated with measures of subclinical target organ damage. JACC Cardiovasc Imaging 2011;4:754–761
36. O’Sullivan C, Duggan J, Lyons S, Thornton J, Lee M, O’Brien E. Hypertensive target-organ damage in the very elderly. Hypertension 2003;42:130–135
37. Kim DH, Kim J, Kim JM, Lee AY. Increased brachial-ankle pulse wave velocity is independently associated with risk of cerebral ischemic small vessel disease in elderly hypertensive patients. Clin Neurrol Neurosurg 2008;110:599–604
38. Brandts A, van Elderen SG, Westenberg JJ, et al. Association of aortic arch pulse wave velocity with left ventricular mass and lacunar brain infarcts in hypertensive patients: assessment with MR imaging. Radiology 2009;253:681–688
39. Choi JC, Lee JS, Kang SY, Kang JH, Bae JM, Lee DH. Limitation of brachial-ankle pulse wave velocity in assessing the risk of stroke: importance of instantaneous blood pressure. Cerebrovasc Dis 2009;27:417–425
40. Kearney-Schwartz A, Rossignol P, Bracard S, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke 2009;40:1229–1236